3-羟化酶1(P3H1)与癌症发展有关,但尚未对P3H1进行泛癌症分析。在这项研究中,第一次,与P3H1相关的方面,如mRNA表达,任何突变,启动子甲基化,和预后意义,P3H1与临床病理参数的关系,药物敏感性,和免疫细胞浸润通过搜索包括癌症基因组图谱(TCGA),基因型-组织表达(GTEx),cBioPortal,和使用生物信息学工具的肿瘤免疫评估资源(TIMER2.0)。结果表明,与正常组织相比,P3H1在大多数肿瘤中的显著差异表达。与临床预后密切相关。泛癌Cox回归分析显示,在低级别脑胶质瘤患者中,高P3H1表达与低总生存率显著相关。肾透明细胞癌,肾上腺皮质癌,肝细胞癌,间皮瘤,肉瘤,葡萄膜黑色素瘤,膀胱尿路上皮癌,肾乳头状细胞癌,肾发色,胸腺瘤,和甲状腺癌。P3H1基因甲基化与其表达呈负相关。P3H1与浸润细胞显著相关,免疫相关基因,肿瘤突变负荷,微卫星不稳定,和失配修复。最后,发现P3H1表达与对9种药物的敏感性之间存在显着相关性。因此,P3H1表达增强与多种肿瘤的不良预后相关,这可能是由于其在肿瘤免疫调节和肿瘤微环境中的作用。这种泛癌分析为了解P3H1在不同癌症肿瘤发生中的功能提供了见解,并为后续进一步深入研究提供了理论基础。
Prolyl 3-hydroxylase 1 (
P3H1) has been implicated in cancer development, but no pan-cancer analysis has been conducted on
P3H1. In this study, for the first time, aspects associated with
P3H1, such as the mRNA expression, any mutation, promoter methylation, and prognostic significance, the relationship between
P3H1 and clinicopathological parameters, drug sensitivity, and immune cell infiltration were investigated by searching several databases including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), cBioPortal, and The Tumor Immune Evaluation Resource (TIMER2.0) using bioinformatics tools. The findings indicate significant differential expression of P3H1 in most tumors when compared to normal tissues, with a strong association with clinical prognosis. A pan-cancer Cox regression analysis revealed that high P3H1 expression is significantly associated with low overall survival in patients with brain lower grade glioma, kidney clear cell carcinoma, adrenocortical cancer, liver hepatocellular carcinoma, mesothelioma, sarcoma, uveal melanoma, bladder urothelial carcinoma, kidney papillary cell carcinoma, kidney chromophobe, thymoma, and thyroid carcinoma. A negative correlation was observed between
P3H1 DNA methylation and its expression. P3H1 is significantly associated with infiltrating cells, immune-related genes, tumor mutation burden, microsatellite instability, and mismatch repair. Finally, A significant correlation was found between P3H1 expression and sensitivity to nine drugs. Thus, enhanced P3H1 expression is associated with poor prognosis in a variety of tumors, which may be due to its role in tumor immune regulation and tumor microenvironment. This pan-cancer analysis provides insight into the function of P3H1 in tumorigenesis of different cancers and provides a theoretical basis for further in-depth studies to follow.